Company profile
GT Biopharma, Inc.
NASDAQ:GTBPBiotechnology: Pharmaceutical Preparations
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03214666 | phase1_2 | terminated | 2020-01-01 | 2021-08-02 | GT Biopharma, Inc. | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies |
FDA applications (0)
No records yet.